Retatrutide vs Mounjaro and Ozempic: key differences
In brief: Mounjaro is tirzepatide, Ozempic is semaglutide, and retatrutide (LY3437943) is an investigational compound. Their receptor profiles differ; this does not establish comparative effectiveness or suitability. Semaglutide acts at the GLP-1 receptor, while retatrutide is studied as an agonist of GLP-1, GIP and glucagon receptors. That difference describes mechanisms—not proof that retatrutide produces better outcomes. Ozempic is a specific semaglutide brand with locally approved indications; retatrutide remains investigational, and clinical-trial findings do not make research materials medicines.
Published: · Last reviewed:
Warning: These materials are strictly for in-vitro laboratory research. Not for human or veterinary use.
Retatrutide laboratory reference →
One receptor pathway versus three
Semaglutide is a GLP-1 receptor agonist. Retatrutide (LY3437943) is described in peer-reviewed clinical research as a GIP, GLP-1 and glucagon receptor agonist. Receptor targets are a pharmacological distinction; counting them does not establish greater efficacy, safety or suitability.
Ozempic’s label is not the same as research status
Ozempic is a brand of semaglutide. Its approved indications are those in the current product information authorized for the relevant jurisdiction; findings about semaglutide or another semaglutide product do not automatically expand the Ozempic label. Retatrutide is an investigational compound, not an approved medicine. A registered or published study is evidence of research, not authorization.
How to interpret comparisons
The cited retatrutide phase 2 publications study retatrutide in their specified populations; they are not head-to-head proof that it is superior to semaglutide or Ozempic. Meaningful comparisons require appropriately designed studies and assessment of population, dose, duration, endpoints and harms. This research overview is not medical advice, and catalog research materials are not for human use.
Where Mounjaro (tirzepatide) fits
Mounjaro is a brand of tirzepatide; its authorised product information is jurisdiction-specific. Tirzepatide is described as targeting GIP and GLP-1 receptors, whereas retatrutide is studied across GIP, GLP-1 and glucagon receptor pathways. These are mechanistic distinctions, not a head-to-head result. The cited retatrutide phase 2 studies do not prove superiority over Mounjaro, tirzepatide or Ozempic. Consult current official product information for authorised indications; this comparison is not treatment advice.
| Research distinction | Ozempic / semaglutide | Retatrutide / LY3437943 |
|---|---|---|
| Receptor targets | GLP-1 | GLP-1, GIP and glucagon |
| Regulatory context | Brand; check current local product information | Investigational; not an approved medicine |
| Do these facts establish superiority? | No | No |
Research references
- Ozempic: European public assessment report — European Medicines Agency, EMA Ozempic product information
- Semaglutide for the treatment of overweight and obesity: A review. — Diabetes, Obesity and Metabolism / PubMed, PMID 36254579
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. — The New England Journal of Medicine / PubMed, PMID 37366315
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. — The Lancet / PubMed, PMID 37385280
- Mounjaro: European public assessment report — European Medicines Agency, EMA Mounjaro product information
Reference questions
Does targeting three receptors mean retatrutide works better than semaglutide?
No. Receptor count alone cannot predict comparative clinical outcomes. Those require suitable direct evidence; the cited retatrutide phase 2 publications do not establish superiority over semaglutide or Ozempic.
Is Ozempic the same as investigational retatrutide?
No. Ozempic is a semaglutide brand with jurisdiction-specific approved indications. Retatrutide is a separate investigational compound and is not approved as a medicine.
Can this comparison guide treatment or use of a catalog item?
No. It is an educational summary of published research, not treatment guidance. Research materials offered in a catalog are not medicines and are not for human use.